Barbara L. Banbury

Jan 8, 2025 | nature.com | Jyoti S. Mayadev |Dmitriy Zamarin |Heather A. Lankes |Barbara L. Banbury |Cara Mathews |David M. O’Malley | +1 more

AbstractCombined immune checkpoint blockade (ICB) and chemoradiation (CRT) is approved in patients with locally advanced cervical cancer (LACC) but optimal sequencing of CRT and ICB is unknown. NRG-GY017 (NCT03738228) was a randomized phase I trial of atezolizumab (anti-PD-L1) neoadjuvant and concurrent with CRT (Arm A) vs. concurrent with CRT (Arm B) in patients with high-risk node-positive LACC.